Hyperintense acute reperfusion marker is associated with higher contrast agent dosage in acute XXXX .

@entity1 @entity64 @entity2288 @entity548
OBJECTIVE: The hyperintense acute reperfusion marker (HARM) on fluid-attenuated inversion recovery (FLAIR) images is associated with blood-brain barrier (BBB) permeability changes. The aim of this study was to examine the influence of contrast agent dosage on HARM incidence in acute @entity64 @entity1 . METHODS: We prospectively included 529 acute @entity64 @entity1 (204 females, median age 71  years). @entity1 underwent a first @entity64 -MRI within 24  hours from symptom onset and had a follow-up on day 2. The contrast agent @entity2288 was administered to the @entity1 for perfusion imaging or MR angiography. The total dosage was calculated as ml/kg body weight and ranged between 0.04 and 0.31  mmol/kg on the first examination. The incidence of HARM was evaluated on day 2 FLAIR images. RESULTS: HARM was detected in 97 @entity1 (18.3  %). HARM incidence increased significantly with increasing dosages of @entity2288 . Also, HARM positive @entity1 were significantly older. HARM was not an independent predictor of worse clinical outcome, and we did not find an association with increase risk of @entity548 . CONCLUSIONS: A higher dosage of @entity2288 in acute @entity64 @entity1 on initial MRI is associated with increased HARM incidence on follow-up. MRI studies on BBB should therefore standardize contrast agent dosages. KEY POINTS:     Hyperintense acute reperfusion marker on MRI indicates blood-brain barrier disruption.     This observational study on @entity64 @entity1 characterizes HARM.     Incidence depends on contrast agent dosage on the previous day.     HARM is also associated with older age and poor kidney function.     Interpretation of HARM must take dosage into consideration.
